Added to YB: 2024-10-10
Pitch date: 2024-10-08
MEDP [bullish]
Medpace Holdings, Inc.
+26.87%
current return
Author Info
Long-Term Pick shares in-depth stock analysis on high-quality stocks with growth potential. Sign up for the newsletter.
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Market Cap
N/A
Pitch Price
$339.02
Price Target
435.00 (+1%)
Dividend
N/A
EV/EBITDA
18.14
P/E
26.45
EV/Sales
N/A
Sector
Life Sciences Tools and Services
Category
value
Medpace: Well-Diversified CRO Service Provider Undervalued By 13%
MEDP: CRO focused on late-stage drug dev for small/mid biotech. Strong moat, $2.9B backlog, 14.6% YoY rev growth. Risks: recent cancellations, innovation needs. Undervalued by 13%, $394.83 fair price. 16.5% 5yr CAGR, 17.53% insider ownership. Bull case: $435 PT, 29% upside.
Read full article (8 min)